Lisata Therapeutics (Lisata Therapeutics) Float Percentage Of Total Shares Outstanding : 84.02% (As of May. 15, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lisata Therapeutics's float shares is 6.98 Mil. Lisata Therapeutics's total shares outstanding is 8.31 Mil. Lisata Therapeutics's float percentage of total shares outstanding is 84.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lisata Therapeutics's Insider Ownership is 16.67%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lisata Therapeutics's Institutional Ownership is 3.68%.

Lisata Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Lisata Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	6.98	/	8.31
	=	84.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics (Lisata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0HS8:UK

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Executives

David W. Slack	director, officer: President & CBO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti	director	P.O. BOX 544, BUELLTON CA 93427
Steven S Myers	director	4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck	officer: EVP, R&D and CMO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo	officer: CLO, SVP of Corp Dev	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo	director, officer: Chief Executive Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo	officer: SVP and CFO	CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo	officer: See Remarks	13 FOX MEADOW RD, SCARSDALE NY 10583
Anford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117